Business Description
Burning Rock Biotech Ltd
ISIN : US12233L2060
Share Class Description:
BNR: ADRTotal Employee Number:
667Description
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.77 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.87 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -4.86 | |||||
Beneish M-Score | -2.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.5 | |||||
3-Year EBITDA Growth Rate | 66.9 | |||||
3-Year EPS without NRI Growth Rate | 63.2 | |||||
3-Year FCF Growth Rate | 60.5 | |||||
3-Year Book Growth Rate | -23.6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.14 | |||||
9-Day RSI | 52.12 | |||||
14-Day RSI | 49.69 | |||||
3-1 Month Momentum % | -66.37 | |||||
6-1 Month Momentum % | -76.25 | |||||
12-1 Month Momentum % | 54.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.05 | |||||
Quick Ratio | 2.81 | |||||
Cash Ratio | 1.94 | |||||
Days Inventory | 155.7 | |||||
Days Sales Outstanding | 122.61 | |||||
Days Payable | 89.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | 4.37 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.55 | |||||
Operating Margin % | -11.42 | |||||
Net Margin % | -11.58 | |||||
EBITDA Margin % | -11.65 | |||||
FCF Margin % | -6.67 | |||||
OCF Margin % | -6.67 | |||||
ROE % | -10.92 | |||||
ROA % | -7.29 | |||||
ROIC % | -23.96 | |||||
3-Year ROIIC % | -269.65 | |||||
ROC (Joel Greenblatt) % | -54.96 | |||||
ROCE % | -10.36 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.39 | |||||
PB Ratio | 1.34 | |||||
Price-to-Tangible-Book | 1.34 | |||||
EV-to-EBIT | -5.06 | |||||
EV-to-EBITDA | -5.06 | |||||
EV-to-Revenue | 0.59 | |||||
EV-to-FCF | -8.83 | |||||
Price-to-GF-Value | 1.27 | |||||
| Price-to-Net-Current-Asset-Value | 1.61 | |||||
| Price-to-Net-Cash | 3.96 | |||||
Earnings Yield (Greenblatt) % | -19.76 | |||||
FCF Yield % | -4.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BNR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Burning Rock Biotech Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 72.761 | ||
| EPS (TTM) ($) | -0.81 | ||
| Beta | 2.4752 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.44 | ||
| Volatility % | 154.09 | ||
| 14-Day RSI | 49.69 | ||
| 14-Day ATR ($) | 1.00501 | ||
| 20-Day SMA ($) | 9.5315 | ||
| 12-1 Month Momentum % | 54.26 | ||
| 52-Week Range ($) | 4.75 - 41.72 | ||
| Shares Outstanding (Mil) | 10.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Burning Rock Biotech Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Burning Rock Biotech Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-23 10:30 | In 156 days | ||
| Third quarter earnings results for 2026 | 2026-11-20 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-09-08 | In 49 days | ||
| Second quarter earnings results for 2026 | 2026-09-08 | In 49 days | ||
| Annual report for 2025 | 2026-04-28 | 19.06 (-9.02%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 23.46 (-1.22%) | ||
| General meeting for 2025 | 2025-12-23 10:30 | 23.39 (+6.32%) | ||
| Third quarter earnings results for 2025 | 2025-11-20 | 16.03 (+11.86%) | ||
| Second quarter earnings results for 2025 | 2025-09-08 | 8.30 (-4.27%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-22 | 9.86 (+8.59%) |
Show
Entries
Burning Rock Biotech Ltd Frequently Asked Questions
What is Burning Rock Biotech Ltd(BNR)'s stock price today?
The current price of BNR is $9.50. The 52 week high of BNR is $41.72 and 52 week low is $4.75.
When is next earnings date of Burning Rock Biotech Ltd(BNR)?
The next earnings date of Burning Rock Biotech Ltd(BNR) is 2026-09-08 Est..
Does Burning Rock Biotech Ltd(BNR) pay dividends? If so, how much?
Burning Rock Biotech Ltd(BNR) does not pay dividend.
Guru Commentaries on NAS:BNR
No articles.
Press Release
Articles on Burning Rock Biotech Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers